Form 4: Twist Bioscience Director Robert Chess Executes Stock Transactions Under 10b5-1 Plan

Twist Bioscience director Robert Chess exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Robert Chess, a director at Twist Bioscience, engaged in multiple transactions involving the company's stock on December 5, 2024.
• These transactions included the exercise of stock options to acquire 3,504 shares at $8.82 per share.
• He also sold 2,795 shares at a weighted average price of $51.7025 and 709 shares at a weighted average price of $52.4511.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 12, 2024.
• Following these transactions, Mr. Chess directly owns 21,641 shares and indirectly owns 42,528 shares through the Chess 1997 Trust.

Sentiment

Score: 5

Explanation: The document reflects routine insider trading activity under a pre-arranged plan, which is neither positive nor negative.

Risks

• The sale of shares by a director could be perceived negatively by the market, although it was done under a pre-arranged plan.

Industry Context

This filing is a routine disclosure of insider transactions and is common for publicly traded companies. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among corporate insiders to avoid accusations of insider trading.
• The reported transactions are typical for directors who hold stock options and periodically sell shares for personal financial management.
• Comparable companies would also have similar filings when directors exercise options and sell shares.

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment, but are unlikely to significantly affect the company's operations or financial health.

Key Dates

Keywords

Twist Bioscience, Robert Chess, stock options, share sales, Form 4, 10b5-1 plan, insider trading